Should minimal residual disease guide therapy in AML?

Best Practice and Research: Clinical Haematology

Volumn 28, Issue 2-3, 2015, Pages 98-105

  Paietta, Elisabeth ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; AML; Minimal residual disease; MRD

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; BIOASSAY; BONE MARROW; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; REMISSION; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; BONE MARROW; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY;

EID: 84960192961     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2015.10.006     Document Type: Review

References (46)

1. H. Inaba, E. Coustan-Smith, X. Cao, S.B. Pounds, S.A. Shurtleff, K.Y. Wang, and et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia J Clin Oncol 30 2012 3625 3632
2. M.R. Loken, T.A. Alonzo, L. Pardo, R.B. Gerbing, R. Aplenc, L. Sung, and et al. Multidimensional flow cytometry significantly improves upon the morphologic assessment of post-induction marrow remission status-comparison of morphology and multidimensional flow cytometry: a report from the Children's Oncology Group AML Protocol AAML0531 Blood (ASH Annu Meet) 118 2011 abstr 939
3. M.R. Loken, T.A. Alonzo, L. Pardo, R.B. Gerbing, S.C. Raimondi, B.A. Hirsch, and et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group Blood 120 2012 1581 1588
4. E. Paietta, and M. Litzow Minimal residual disease in acute leukemias: are we on the right Path? H.M. Lazarus, R.P. Gale, A. Keating, A. Bacigalupo, R. Munker, K. Atkinson, Hematopoietic cell transplants: concepts, controversies and future directions 2015 Cambridge University Press [in press]
5. D. Grimwade, and M. Tallman Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Res 35 2011 3 7
6. R.B. Walter, H.M. Kantarjian, X. Huang, S.A. Pierce, Z. Sun, H.M. Gundacker, and et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center study J Clin Oncol 28 2010 1766 1771
7. X. Chen, H. Xie, B.L. Wood, R.B. Walter, J.M. Pagel, P.S. Becker, and et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia J Clin Oncol 33 2015 1258 1264
8. S.D. Freeman, P. Virgo, S. Couzens, D. Grimwade, N. Russell, R.K. Hills, and et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patient with acute myeloid leukemia J Clin Oncol 31 2013 4123 4131
9. P. Stow, L. Key, X. Chen, Q. Pan, G.A. Neale, E. Coustan-Smith, and et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia Blood 115 2010 4657 4663
10. L. Maurillo, F. Buccisano, M.I. Del Principe, G. Del Poeta, A. Spagnoli, P. Panetta, and et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia J Clin Oncol 26 2008 4944 4951
11. J.E. Rubnitz, H. Inaba, G. Dahl, R.C. Ribeiro, W.P. Bowman, J. Taub, and et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial Lancet 11 2010 543 552
12. M. Terwijn, W.L.J. van Putten, A. Kelder, V.H. van der Velden, R.A. Brooimans, T. Pabst, and et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study J Clin Oncol 31 2013 3889 3897
13. J.F. San Miguel, M.B. Vidriales, C. Lopez-Berges, J. Díaz-Mediavilla, N. Gutiérrez, C. Cañizo, and et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood 98 2001 1746 1751
14. F. Buccisano, L. Maurillo, M.I. Del Principe, G. Del Poeta, G. Sconocchia, F. Lo-Coco, and et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia Blood 119 2012 332 341
15. E. Paietta Minimal residual disease in AML: coming of age Am Soc Hematol Educ Program 2012 35 42
16. F. Buccisano, L. Maurillo, V. Gattei, G. Del Poeta, M.I. Del Principe, M.C. Cox, and et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia Leukemia 20 2006 1783 1789
17. C. Ganzel, Z. Sun, M. Gönen, J.P. Patel, O. Abdel-Wahab, H.F. Fernandez, and et al. Minimal residual disease assessment by flow cytometry in AML is an independent prognostic factor even after adjusting for cytogenetic/molecular abnormalities Blood (ASH Annu Meet 124 2014 abstr 1016
18. H.F. Fernandez, Z. Sun, X. Yao, M.R. Litzow, S.M. Luger, E.M. Paietta, and et al. Anthracycline dose intensification in acute myeloid leukemia: results of ECOG study E1900 N Engl J Med 361 2009 1249 1259
19. W. Leung, D. Campana, J. Yang, D. Pei, E. Coustan-Smith, K. Gan, and et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia Blood 118 2011 223 230
20. R.B. Walter, S.A. Buckley, J.M. Pagel, B.L. Wood, B.E. Storer, B.M. Sandmaier, and et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission Blood 122 2013 1813 1821
21. A. Butturini, J. Klein, and R.P. Gale Modeling minimal residual disease (MRD)-testing Leukemia Res 27 2003 293 300
22. EuroFlow educational book 2012 Macmillan Publ Ltd
23. B.L. Wood Flow cytometric monitoring of residual disease in acute leukemia M. Czader, Hematological malignancies Methods in molecular biology vol 999 2013 123 136
24. D. Shook, E. Coustan-Smith, R.C. Ribeiro, J.E. Rubnitz, and D. Campana Minimal residual disease quantitation in acute myeloid leukemia Clin Lymphoma Myeloma 9 Suppl. 3 2009 S281 S285
25. D. Grimwade, and S.D. Freeman Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood 124 2014 3345 3355
26. W. Zeijlemaker, J.W. Gratama, and G.J. Schuurhuis Tumor heterogeneity males AML a "moving target" for the detection of residual disease Cytom Part B Clin Cytom 86B 2014 3 14
27. J.J.M. van Dongen, V.H.J. van der Velden, M. Brüggemann, and A. Orfao Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies Blood 125 2015 3996 4009
28. E. Paietta Minimal residual disease in acute leukaemia: a guide to precision medicine ready for prime time? Treat Strategies Haematol Vol. 4 2 2014 45 48
29. J. Helgestad, S. Rosthøj, P. Johansen, K. Varming, and E. Ostergaard Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukemia Pediatr Blood Cancer 57 2011 224 226
30. V.H. van der Velden, P.G. Hoogeveen, R. Pieters, and J.J. van Dongen Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia Br J Haematol 133 2006 382 388
31. M. Vanderhoek, M.B. Juckett, S.B. Perlman, R.J. Nickles, and R. Jeraj Early assessment of treatment response in AML patients using [(18)F]FLT PET imaging Leuk Res 35 2011 310 316
32. A.C.M. Martens, F.W. Schultz, and A. Hagenbeek Nonhomogenous distribution of leukemia in the bone marrow during minimal residual disease Blood 70 1987 1073 1078
33. R. Gale Measureable residual disease (MRD): much ado about nothing? Bone Marrow Transpl 50 2015 163 164
34. N. Hagedorn, C. Acquaviva, E. Fronkova, A. von Stackelberg, A. Barth, U. zur Stadt, and et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group Blood 110 2007 4022 4029
35. B. Patel, L. Rai, G. Buck, S.M. Richards, Y. Mortuza, W. Mitchell, and et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 Br J Haematol 148 2009 80 89
36. L. Zhong, L. Wei, J. Chen, X. Huang, Y. Gong, and Y. Lu WT1 Expression in circulating RNA as a minimal residual disease marker for AML patients after stem-cell transplantation Mol Diagn Ther 2015 Jul 3 [epub ahead of print]
37. M. Kwon, C. Martínez-Laperche, M. Infante, F. Carretero, P. Balsalobre, D. Serrano, and et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism Biol Blood Marrow Transpl 18 2012 1235 1242
38. C. Bachas, G.J. Schuurhuis, Y.G. Assaraf, Z.J. Kwidama, A. Kelder, F. Wouters, and et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse Leukemia 26 2012 1313 1320
39. H.B. Ommen, S. Schnittger, J.V. Jovanovic, I.B. Ommen, H. Hasle, M. Ostergaard, and et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias Blood 115 2010 198 205
40. B. Will, and U. Steidl Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies Best Pract Res Clin Haematol 23 2010 391 401
41. S.M. Chan, and R. Majeti Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia Int J Hematol 98 2013 648 657
42. L.I. Shlush, S. Zandi, A. Mitchell, W.C. Chen, J.M. Brandwein, V. Gupta, and et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia Nature 506 2014 328 333
43. L. Barreyro, B. Will, B. Bartholdy, L. Zhou, T.I. Todorova, R.F. Stanley, and et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS Blood 120 2012 1290 1298
44. M. Askmyr, H. Ågerstam, N. Hansen, S. Gordon, A. Arvanitakis, M. Rissler, and et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP Blood 121 2013 3709 3713
45. E. Waanders, V.H.J. van der Velden, C.E. van der Schoot, F.N. van Leeuwen, S.V. van Reijmersdal, V. de Haas, and et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia Leukemia 25 2011 254 258
46. M. Gönen, Z. Sun, M.E. Figueroa, J.P. Patel, O. Abdel-Wahab, J. Racevskis, and et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase III trial, E1900 Blood 120 2012 2297 2306